This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy.

The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.

In patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy, the investigators aim to determine whether continuous veno-venous haemodialysis with an EMiC®2 filter leads to clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor.

Inclusion Criteria:

• adult patients (≥18 years) in the Critical Care Unit with AKI and sepsis
• clinical decision that citrate based continuous veno-venous haemodialysis (CVVHD) is necessary

Exclusion Criteria:

• lack of consent
• pre-existing dialysis dependent renal failure
• life expectancy <24 hours
• patients with haemoglobin <7g/dL (unless transfused for clinical reasons)
• need for extracorporeal membrane oxygenation (ECMO)

Adult patients with sepsis and acute kidney injury who require renal replacement therapy.